EGFR/HDAC-IN-1
EGFR/HDAC-IN-1 (Compound 22c2) is a potent dual inhibitor of epidermal growth factor receptor (EGFR) and histone deacetylase (HDAC) with IC50 values of 4.81 nM, 119.4 nM and 354.8 nM for EGFR, HDAC1 and HDAC3, respectively. EGFR/HDAC-IN-1 blocks the EGFR signaling pathway and affects the histone acetylation status, thereby inhibiting tumor cell proliferation. EGFR/HDAC-IN-1 is promising for research of non-small cell lung cancer (NSCLC) [1].
Product Specifications
UNSPSC
12352005
Target
EGFR; HDAC
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(NO)CCCCCOC1=C2C(OCCO2)=C3C(NC4=CC(Cl)=CC=C4)=NC=NC3=C1
Molecular Formula
C22H23ClN4O5
Molecular Weight
458.89
References & Citations
[1]Yao K, et al. Synthesis and biological evaluation of novel 4-Arylaminoquinolines derivatives as EGFR/HDAC inhibitors. Bioorg Med Chem Lett. 2025 Jul 1;122:130214.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
